NYSE$ATR

AptarGroup Inc. · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

AptarGroup reported strong Q3 2024 results with growth in proprietary drug delivery systems and increased demand for closure technologies.

AptarGroup's Q3 2024 results showed a 2% increase in both reported and core sales, driven by the Pharma and Closures segments. Net income increased by 19% to $100 million, and adjusted EPS rose by 6% to $1.49.

  • Reported and core sales increased by 2%.
  • Reported EPS increased 17% to $1.48, and adjusted EPS increased 6% to $1.49.
  • Reported net income increased 19% to $100 million.
  • Pharma segment delivered reported sales growth of 8% and core sales growth of 7%.

Headline financials

Total Revenue

$909M

Previous: $893M+1.8%
EPS

$1.48

Previous: $1.39+6.5%
Capital Expenditures

-$210M

Previous: -$231M+9.0%
Free Cash Flow

-$110M

Previous: -$147M+24.9%
Net Income

$100M

Previous: $84.3M+18.7%
Operating Income

$138M

Previous: $119M+15.9%
Gross Profit

$909M

Previous: $893M+1.8%
Cash & Equivalents

$326M

Previous: $152M+114.8%
Total Assets

$4.63B

Previous: $4.3B+7.6%
Stock-Based Comp

$10.4M

Previous: $10.7M-2.3%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$909M

Q3 2024+1.8%vs Q3 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $893M total across 3 segments · Q3 2023

  • Pharma
    $389M+13.3%
  • Beauty
    $324M-10.0%
  • Closures
    $180M+34.6%

Forward guidance

Aptar anticipates a solid finish to a strong year, with top-line growth expected in Q4 despite some customer inventory adjustments. Pharma is expected to finish within its core sales long-term target range, and Closures expects a strong finish with healthy margin improvements. Beauty continues to focus on the bottom line in a tough macro environment.

Tailwinds

  • Top line is expected to grow in the fourth quarter.
  • Pharma business should finish full year 2024 within its core sales long-term target range of 7-11%.
  • Pharma segment will deliver solid, double-digit adjusted EBITDA growth in 2024 due in part to sales of higher value products and royalties.
  • Closures segment has returned to growth and we expect a strong finish to 2024, with healthy adjusted EBITDA margin improvements over the prior year.
  • Full year adjusted EPS would be in the range of $5.34 to $5.42, a double-digit increase over full year 2023.

Headwinds

  • Some customers have indicated seasonal inventory right-sizing in the beauty and cough & cold end markets.
  • Beauty is battling a tough macro environment.
  • Innovation, cost mitigation, improved operational leverage and accelerating efficiencies remain key priorities for our teams.
  • Aptar currently expects earnings per share for the fourth quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30.
  • This guidance is based on an effective tax rate range of 20% to 22% with a comparable adjusted prior year effective tax rate of 24%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro